These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38982693)

  • 1. Successful Treatment of Switching EGFR-TKIs for Advanced Lung Adenocarcinoma Due to Interstitial Lung Disease: A Case Report.
    Zeng X; Wang T; Tang Y; Liao X; Wang J; Li Y
    Curr Cancer Drug Targets; 2024 Jul; ():. PubMed ID: 38982693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
    Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
    Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
    Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
    Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.
    Xu T; Wu H; Jin S; Min H; Zhang Z; Shu Y; Wen W; Guo R
    Medicine (Baltimore); 2017 Aug; 96(33):e7732. PubMed ID: 28816950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
    Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
    Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation.
    Chen J; Wu X; Wang J
    Front Oncol; 2022; 12():898586. PubMed ID: 35957876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: EGFR-TKI rechallenge after osimertinib-induced interstitial lung disease: a case report and literature review.
    Gu X; Zhong Y; Huang H
    Front Pharmacol; 2024; 15():1410684. PubMed ID: 38895622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
    Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
    Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Almonertinib-induced interstitial lung disease: A case report.
    Jiang T; Luo Y; Wang B
    Medicine (Baltimore); 2021 Jan; 100(3):e24393. PubMed ID: 33546082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality.
    Zhou Q; Hu Z; Li X; Tang X
    BMC Pulm Med; 2023 Mar; 23(1):79. PubMed ID: 36890493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal interstitial lung disease associated with icotinib.
    Zhang J; Zhan Y; Ouyang M; Qin Y; Zhou C; Chen R
    J Thorac Dis; 2014 Dec; 6(12):E267-71. PubMed ID: 25590006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: sequential use of almonertinib based on the
    Wang R; Yu S; Yu L; Zhao J; Jiao S; Wang Q; Wu Y
    Transl Cancer Res; 2022 Jun; 11(6):1836-1843. PubMed ID: 35836508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report.
    Chen S; Yu Q; Jiang W; Lu Y; Zhao Y; Wang H
    Front Med (Lausanne); 2023; 10():1168220. PubMed ID: 37457583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
    Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy.
    Zheng X; Liu G; Wang S; Zhang Y; Bao W; Deng D; Mao W; Fang M
    Oncol Lett; 2014 Oct; 8(4):1563-1566. PubMed ID: 25202368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
    Shi YK; Wang L; Han BH; Li W; Yu P; Liu YP; Ding CM; Song X; Ma ZY; Ren XL; Feng JF; Zhang HL; Chen GY; Han XH; Wu N; Yao C; Song Y; Zhang SC; Song W; Liu XQ; Zhao SJ; Lin YC; Ye XQ; Li K; Shu YQ; Ding LM; Tan FL; Sun Y
    Ann Oncol; 2017 Oct; 28(10):2443-2450. PubMed ID: 28945850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report.
    Wu L; Fang C; Zhao W; Li D; Tang S; Li X; Ji M
    Ann Transl Med; 2022 Jan; 10(2):116. PubMed ID: 35282062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.